Rabbit Anti-APOBEC1 (Apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 1)
RNA editing is an important mechanism for regulating genetic plasticity through the generation of alternative protein productsfrom a single structural gene. Substitutional RNA editing employsa variety of genetic mechanisms, the biochemical basis of whichhas been elucidated following the development of in vitro assaysthat recapitulate important elements of this process. There are two typesof substitutional RNA exist in mammals, namely A-to-I and C-to-URNA editing. The best-characterized example of C-to-U RNA editing involves the nuclear transcript encoding intestinal apolipoprotein B(apo B)). Apo B RNA editing changes a CAA to a UAA stop codon,generating a truncated protein, apoB48. The functional complex includes a minimal corecomposed of apobec-1 and ACF, that functionas an adaptor protein by binding both the deaminase and the RNA substrate. The RNA binding proteins also include CUGBP2 which along with Apobec-1 binds to the consensus binding sequence UUUN (A/U) U, present in c-myc, VEGF and Cyclooxygenase-2 (COX2).
Apobec-1, a 236aa protein in human (chr 12p13.1) an RNA specific cytidine deaminase, is essential but not efficient for apo B editing activity, there being a requirement for other protein factor. Apobec-1 is a dimer with the composite active site assembled through interaction of each monomer; In addition it is an RNA-binding protein that binds to the consensus sequence UUUN (A/U) U located within the terminal loop of apo B RNA. But finally it forms the minimal component of the core-editing enzyme along with ACF.
Applications
Suitable for use in ELISA and Western Blot. Other applications not tested.
Recommended Dilutions
ELISA: 0.5-1ug/ml; Control peptide can be used to coat ELISA plates at 1ug/ml Western Blot: 1-10ug/ml (ECL) Optimal dilutions to be determined by the researcher.
Control Peptide
A2298-88A3: APOBEC1, Human, Control Peptide (Apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 1)
Storage and Stability
Lyophilized and reconstituted products are stable for 12 months after receipt at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Immunogen
Synthetic peptide corresponding to 16aa at the C-Terminal of human Apobec-1, conjugated to KLH.
Form
Supplied as a liquid in PBS, 0.1% BSA.
Purity
Purified by affinity chromatography.
Specificity
Recognizes human APOBEC1.
